Medicare D 补贴与激素治疗持续性和依从性的种族差异
研究纳入2006至2007年接受乳腺癌手术且至少配取一次口服激素治疗的≥65岁女性,比较不同种族或族裔的持续性与依从性。西班牙裔77%和黑人70%获补贴,白人21%。未获补贴者中断治疗风险更高,获补贴者间无持续性差异。
要点
- 西班牙裔77%和黑人70%获补贴,白人21%。
- 2年时黑人69%和西班牙裔70%持续用药,白人61%。
- 未获补贴者中断治疗风险更高,获补贴者间无持续性差异。
核心结论
- 获得处方补贴与白人、黑人和西班牙裔女性乳腺癌激素治疗持续性显著改善及持续性无种族或族裔差异相关。
研究设计与样本
- 全国性队列研究,纳入2006至2007年接受乳腺癌手术且至少配取一次口服乳腺癌激素治疗的≥65岁女性,样本量25,111例。
主要发现
- 西班牙裔77%和黑人70%获补贴,白人21%。
- 2年时黑人69%和西班牙裔70%持续用药,白人61%。
- 未获补贴者中断治疗风险更高:白人HR 1.83(95%CI 1.70至1.95),黑人HR 2.09(95%CI 1.73至2.51),西班牙裔HR 3.00(95%CI 2.37至3.89)。
- 未获补贴者存在的种族或族裔持续性差异在获补贴者中不存在或反转。
- 三个获补贴种族或族裔组依从性均高于三个未获补贴组,黑人女性差异最小。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To investigate the role of out-of-pocket cost supports through the Medicare Part D Low-Income Subsidy on disparities in breast cancer hormonal therapy persistence and adherence by race or ethnicity. Methods A nationwide cohort of women age ≥ 65 years with a breast cancer operation between 2006 and 2007 and at least one prescription filled for oral breast cancer hormonal therapy was identified from all Medicare D enrollees. The association of race or ethnicity with nonpersistence (90 consecutive days with no claims for a hormonal therapy prescription) and nonadherence (medication possession rate < 80%) was examined. Survival analyses were used to account for potential differences in age, comorbidity, or intensity of other treatments. Results Among the 25,111 women in the study sample, 77% of the Hispanic and 70% of the black women received a subsidy compared with 21% of the white women. By 2 years, 69% of black and 70% of Hispanic patients were persistent compared with 61% of white patients. In adjusted analyses, patients in all three unsubsidized race or ethnicity groups had greater discontinuation than subsidized groups (white patients: hazard ratio [HR], 1.83; 95% CI, 1.70 to 1.95; black patients: HR, 2.09; 95% CI, 1.73 to 2.51; Hispanic patients: HR, 3.00; 95% CI, 2.37 to 3.89). Racial or ethnic persistence disparities that were present for unsubsidized patients were not present or reversed among subsidized patients. All three subsidized race or ethnicity groups also had higher adherence than all three unsubsidized groups, although with the smallest difference occurring in black women. Conclusion Receipt of a prescription subsidy was associated with substantially improved persistence to breast cancer hormonal therapy among white, black, and Hispanic women and lack of racial or ethnic disparities in persistence. Given high subsidy enrollment among black and Hispanic women, policies targeted at low-income patients have the potential to also substantially reduce racial and ethnic disparities.
引用
- Biggers A, Shi Y, Charlson J, et al. Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy. J Clin Oncol. 2016. PMID: 27998232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。